BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21760594)

  • 21. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
    Renneville A; Boissel N; Zurawski V; Llopis L; Biggio V; Nibourel O; Philippe N; Thomas X; Dombret H; Preudhomme C
    Cancer; 2009 Aug; 115(16):3719-27. PubMed ID: 19536888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
    Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
    Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. WT1 isoform expression pattern in acute myeloid leukemia.
    Luna I; Such E; Cervera J; Barragán E; Ibañez M; Gómez-Seguí I; López-Pavía M; Llop M; Fuster O; Dolz S; Oltra S; Alonso C; Vera B; Lorenzo I; Martínez-Cuadrón D; Montesinos P; Senent ML; Moscardó F; Bolufer P; Sanz MA
    Leuk Res; 2013 Dec; 37(12):1744-9. PubMed ID: 24211094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia.
    Barragán E; Cervera J; Bolufer P; Ballester S; Martín G; Fernández P; Collado R; Sayas MJ; Sanz MA
    Haematologica; 2004 Aug; 89(8):926-33. PubMed ID: 15339675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
    Weisser M; Kern W; Rauhut S; Schoch C; Hiddemann W; Haferlach T; Schnittger S
    Leukemia; 2005 Aug; 19(8):1416-23. PubMed ID: 15920493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant Wilms' tumor 1 (WT1) mRNA with premature termination codons in acute myeloid leukemia (AML) is sensitive to nonsense-mediated RNA decay (NMD).
    Abbas S; Erpelinck-Verschueren CA; Goudswaard CS; Löwenberg B; Valk PJ
    Leukemia; 2010 Mar; 24(3):660-3. PubMed ID: 20016532
    [No Abstract]   [Full Text] [Related]  

  • 29. Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia.
    Awada H; Durmaz A; Gurnari C; Kishtagari A; Zawit M; Pagliuca S; Visconte V
    Blood Cells Mol Dis; 2021 May; 88():102549. PubMed ID: 33636567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk-Reducing Genetic Variant of Wilms Tumor 1 Gene rs16754 in Korean Patients With BCR-ABL1-Negative Myeloproliferative Neoplasm.
    Kim N; Kim IS; Chang CL; Kang JE; Lee EY; Shin HJ
    Ann Lab Med; 2015 May; 35(3):348-51. PubMed ID: 25932444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients.
    Alonso-Dominguez JM; Tenorio M; Velasco D; Abalo L; Lozano S; Villarrubia J; López-Jimenez J; Grande S; Ayala R
    Cancer Genet; 2012 Apr; 205(4):190-1. PubMed ID: 22559982
    [No Abstract]   [Full Text] [Related]  

  • 32. The significance of detecting WT1 expression in childhood acute leukemias.
    Hu SY; Gu WY; Chen ZX; Wang XL; Cen JN; He HL; Chai YH; Chen CS
    Pediatr Hematol Oncol; 2010 Nov; 27(8):581-91. PubMed ID: 20863155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia.
    Iwasaki T; Sugisaki C; Nagata K; Takagi K; Takagi A; Kojima T; Ito M; Nakamura S; Naoe T; Murate T
    Pathol Int; 2007 Oct; 57(10):645-51. PubMed ID: 17803653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of the Wilms' tumor gene (WT1) in human leukemias.
    Miwa H; Beran M; Saunders GF
    Leukemia; 1992 May; 6(5):405-9. PubMed ID: 1317488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wilms Tumor-1 (WT1) rs16754 Polymorphism and Clinical Outcome in Acute Myeloid Leukemia.
    Ramzi M; Moghadam M; Cohan N
    Turk J Haematol; 2019 Feb; 36(1):67-68. PubMed ID: 30468432
    [No Abstract]   [Full Text] [Related]  

  • 36. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants.
    Siehl JM; Reinwald M; Heufelder K; Menssen HD; Keilholz U; Thiel E
    Ann Hematol; 2004 Dec; 83(12):745-50. PubMed ID: 15340762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 in de novo non-M3 acute myeloid leukemia.
    Luo S; Yu K; Yan QX; Shen ZJ; Wu JB; Chen HM; Gao SM
    Leuk Lymphoma; 2014 Feb; 55(2):349-57. PubMed ID: 23550990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
    Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
    Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.
    Mahlknecht U; Dransfeld CL; Bulut N; Kramer M; Thiede C; Ehninger G; Schaich M
    Leukemia; 2009 Oct; 23(10):1929-32. PubMed ID: 19458626
    [No Abstract]   [Full Text] [Related]  

  • 40. [Correlation between clinical outcome and WT1 detection after hematopoietic stem cell transplantation in acute leukemia].
    Zhao BR; Tang XW; Cen JN; Jin S; Shi XL; Wei XA; Chang WR; Sun AN; Wu DP
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1375-8. PubMed ID: 21756806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.